In one of the most surprising news today, Dynavax Technologies Corporation (NASDAQ:DVAX) has announced that the first clinical data of their HEPLISAV has shown increase in the protection rate for chronic kidney disease patients. The data will be presented publicly in a poster session on Saturday, October 31, 2009 at the Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania.

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops product candidates like Toll-like Receptor also known as TLR. HEPLISAV is a Phase 3 adult hepatitis B vaccine that provides increased and rapid protection to the patients with fewer doses compare to the current licensed vaccines available in the market. During the Phase 3 trial of HEPLISAV around 2500 individuals were vaccinated with

...

The Company’s business plan is to develop its proprietary technology designed to treat moderate to severe liver maladies, such as elevated liver enzymes and the Hepatitis C viral infection, (the “Liver Health Formula”) as an over-the-counter medication and as a United States Food and Drug Administration (”FDA”) approved pharmaceutical. To date, the Company’s intellectual property covering the Liver Health Formula comprises of patent applications in the United States, Europe and Canada and four European Drug Master File applications.

Caleco Pharma Corp. shares are traded in the United States on the OTC Bulletin Board (OTCBB: CAEH) and in Germany on the Frankfurt Stock Exchange (WKN: A0N9Y0/ Symbol:T3R.FSE).

Related posts Jim Holmes, CEO of Lifeline ...

On the very first day of the week, Depomed Inc has come out with good news that their new shingles pain drug has met the study goal. Depomed has announced that they have achieved success in the late stage clinical trial of a drug that will be used for the treatment of pain following viral infection shingles. The news of this success had a straight impact on Depomed’s shares and it went up immediately after the news was announced.

Earlier in the session Depomed stocks advanced around $1.35 which is around 30.6 percent, later it went up to $5.76 and finally the shares peaked up to $6.21 which is their highest price since June 2006. Approximately around 288,000 shares were traded on an average in one single day and more

...

bSummary/bbrbr Scancell is developing a product platform that uniquely stimulates the immune system to treat disease. The corporate strategy is simple – spend the next two years conducting “proof of concept” studies in melanoma patients, run animal trials in parallel targeting angiogenesis to confirm it as a platform technology, and then sell off the technology to the highest bidder. To use a baseball analogy, Scancell is heading to the plate and swinging for the fences. With a differentiated technology and a focused plan, we think this Company has what it takes to circle the bases. pBKey points:/BBRBRul pli type=squarebA high risk, high reward proposition/bbr As history has shown, the path to market for therapeutic cancer vaccines is not going to be an easy one. Many bodies litter the road and the science is still very much evolving, but to the winners go the spoils. Using a conservative set of assumptions and a heavily discounted valuation methodology, we still derived a base case value for Scancell ...